These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 9715276)

  • 21. Cot protooncoprotein activates the dual specificity kinases MEK-1 and SEK-1 and induces differentiation of PC12 cells.
    Hagemann D; Troppmair J; Rapp UR
    Oncogene; 1999 Feb; 18(7):1391-400. PubMed ID: 10050876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
    Carlomagno F; Vitagliano D; Guida T; Ciardiello F; Tortora G; Vecchio G; Ryan AJ; Fontanini G; Fusco A; Santoro M
    Cancer Res; 2002 Dec; 62(24):7284-90. PubMed ID: 12499271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RET activation by germline MEN2A and MEN2B mutations.
    Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
    Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ultraviolet light induces redox reaction-mediated dimerization and superactivation of oncogenic Ret tyrosine kinases.
    Kato M; Iwashita T; Takeda K; Akhand AA; Liu W; Yoshihara M; Asai N; Suzuki H; Takahashi M; Nakashima I
    Mol Biol Cell; 2000 Jan; 11(1):93-101. PubMed ID: 10637293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease.
    Pelet A; Geneste O; Edery P; Pasini A; Chappuis S; Atti T; Munnich A; Lenoir G; Lyonnet S; Billaud M
    J Clin Invest; 1998 Mar; 101(6):1415-23. PubMed ID: 9502784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck.
    Bocciardi R; Mograbi B; Pasini B; Borrello MG; Pierotti MA; Bourget I; Fischer S; Romeo G; Rossi B
    Oncogene; 1997 Nov; 15(19):2257-65. PubMed ID: 9393871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivo.
    Chen YQ; Zhou YQ; Fisher JH; Wang MH
    Oncogene; 2002 Sep; 21(41):6382-6. PubMed ID: 12214279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes.
    Castellone MD; Cirafici AM; De Vita G; De Falco V; Malorni L; Tallini G; Fagin JA; Fusco A; Melillo RM; Santoro M
    Oncogene; 2003 Jan; 22(2):246-55. PubMed ID: 12527893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.
    Melillo RM; Santoro M; Ong SH; Billaud M; Fusco A; Hadari YR; Schlessinger J; Lax I
    Mol Cell Biol; 2001 Jul; 21(13):4177-87. PubMed ID: 11390647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
    Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM
    Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine.
    Kato M; Takeda K; Kawamoto Y; Iwashita T; Akhand AA; Senga T; Yamamoto M; Sobue G; Hamaguchi M; Takahashi M; Nakashima I
    Cancer Res; 2002 Apr; 62(8):2414-22. PubMed ID: 11956105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential.
    Zhou YQ; He C; Chen YQ; Wang D; Wang MH
    Oncogene; 2003 Jan; 22(2):186-97. PubMed ID: 12527888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential.
    Cirafici AM; Salvatore G; De Vita G; Carlomagno F; Dathan NA; Visconti R; Melillo RM; Fusco A; Santoro M
    Endocrinology; 1997 Apr; 138(4):1450-5. PubMed ID: 9075701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The JNK/SAPK activator mixed lineage kinase 3 (MLK3) transforms NIH 3T3 cells in a MEK-dependent fashion.
    Hartkamp J; Troppmair J; Rapp UR
    Cancer Res; 1999 May; 59(9):2195-202. PubMed ID: 10232608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.
    Cuccuru G; Lanzi C; Cassinelli G; Pratesi G; Tortoreto M; Petrangolini G; Seregni E; Martinetti A; Laccabue D; Zanchi C; Zunino F
    J Natl Cancer Inst; 2004 Jul; 96(13):1006-14. PubMed ID: 15240784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes.
    Amundadottir LT; Leder P
    Oncogene; 1998 Feb; 16(6):737-46. PubMed ID: 9488037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins.
    Salvatore D; Barone MV; Salvatore G; Melillo RM; Chiappetta G; Mineo A; Fenzi G; Vecchio G; Fusco A; Santoro M
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3898-907. PubMed ID: 11061555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rac-1 dependent stimulation of the JNK/SAPK signaling pathway by Vav.
    Crespo P; Bustelo XR; Aaronson DS; Coso OA; Lopez-Barahona M; Barbacid M; Gutkind JS
    Oncogene; 1996 Aug; 13(3):455-60. PubMed ID: 8760286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations.
    Rossel M; Pasini A; Chappuis S; Geneste O; Fournier L; Schuffenecker I; Takahashi M; van Grunsven LA; Urdiales JL; Rudkin BB; Lenoir GM; Billaud M
    Oncogene; 1997 Jan; 14(3):265-75. PubMed ID: 9018112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Geldanamycins trigger a novel Ron degradative pathway, hampering oncogenic signaling.
    Germano S; Barberis D; Santoro MM; Penengo L; Citri A; Yarden Y; Gaudino G
    J Biol Chem; 2006 Aug; 281(31):21710-21719. PubMed ID: 16740632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.